Interestingly, molecular subtyping of breast cancers in the clinic is routinely based on immunohistochemical analysis of HER2-, ESR1- and PGR-expression from tumor biopsies and is rarely assessed at a transcriptional level [29]. This evidence concerns the gene ERBB2 and neoplasm.